US Patent No: 7,476,509

Number of patents in Portfolio can not be more than 2000

Compounds and methods for modulating functions of nonclassical cadherins

ALSO PUBLISHED AS: 20040175361

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and/or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ADHEREX TECHNOLOGIES, INC.OTTAWA31

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blaschuk, Orest W Westmount, CA 107 351
Michaud, Stephanie D Ottawa, CA 12 17

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Adherex Technologies, Inc. (9)
6,472,367 Compounds and methods for modulating OB-cadherin mediated cell adhesion 8 1998
6,277,824 Compounds and methods for modulating adhesion molecule function 10 1998
6,358,920 Compounds and methods for modulating nonclassical cadherin-mediated functions 15 1998
6,110,747 Compounds and methods for modulating tissue permeability 11 1998
6,303,576 Compounds and methods for modulating .beta.-catenin mediated gene expression 6 1999
6,433,149 Compounds and methods for inhibiting cancer metastasis 11 1999
6,391,855 Compounds and methods for modulating junctional adhesion molecule-mediated functions 17 1999
6,472,368 Compounds and methods for modulating adhesion molecule function 7 1999
6,310,177 Compounds and methods for modulating tissue permeability 6 2000
 
MCGILL UNIVERSITY (9)
6,031,072 Compounds and methods for modulating cell adhesion 30 1997
6,169,071 Compounds and methods for modulating cell adhesion 21 1997
6,207,639 Compounds and methods for modulating neurite outgrowth 8 1998
6,346,512 Compounds and methods for modulating cell adhesion 8 1999
6,562,786 Compounds and methods for modulating apoptosis 6 1999
6,333,307 Compounds and method for modulating neurite outgrowth 5 1999
6,417,325 Compounds and methods for cancer therapy 6 1999
6,465,427 Compounds and methods for modulating cell adhesion 6 1999
6,326,352 Compounds and methods for modulating cell adhesion 11 2000
 
DOHENY EYE INSTITUTE (6)
5,643,781 DNA encoding protocadherin-42 14 1992
5,597,725 Cadherin-specific antibodies and hybridoma cell lines 22 1994
5,639,634 Cadherin polynucleotides 18 1994
5,646,250 Cadherin polypeptides 41 1994
5,663,300 Protocadherin-42 8 1995
5,708,143 Protocadherin materials and methods 14 1995
 
ADHEREX INC. (2)
6,203,788 Compounds and methods for regulating cell adhesion 8 1997
6,248,864 Compounds and methods and modulating tissue permeability 7 1997
 
Angstrom Pharmaceuticals, Inc. (1)
6,936,587 Anti-invasive and anti-angiogenic compositions 2 2003
 
BIOGEN IDEC INTERNATIONAL HOLDING LTD. (1)
5,811,514 Integrin blocking molecule 12 1995
 
GLAXOSMITHKLINE BIOLOGICALS S.A. (1)
6,600,013 Moraxella catarrhalis BASB034 polypeptides and uses thereof 2 2001
 
ISHIHARA SANGYO KAISHA, LTD. (1)
5,869,683 Processes for producing 1-substituted-2-cyanoimidazole compounds 1 1997
 
JAPAN TOBACCO INC. (1)
5,916,771 Production of a multimeric protein by cell fusion method 120 1996
 
La Jolla Cancer Research Foundation (1)
5,585,351 T-cadherin adhesion molecule 27 1994
 
NEW YORK UNIVERSITY (1)
6,713,450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 36 2001
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
5,610,281 Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes 24 1994
 
THE GENERAL HOSPITAL CORPORATION (1)
6,060,595 Inhibition of viral replication 3 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
6,083,713 Cloning and expression of .beta.APP-C100 receptor (C100-R) 3 1995
 
The Research Foundation of State University of New York (1)
5,455,228 Peptidase resistant thrombin receptor peptide ligand 11 1993
 
Other [Check patent profile for assignment information] (2)
5,895,748 Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies 10 1996
5,997,866 Panel of antibodies for detecting cadherins, catenins and plaque proteins in tissues and method of using the panel 10 1999

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 13, 2016
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 13, 2020
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00